These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30529793)

  • 41. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Corifollitropin alfa compared with follitropin beta in GnRH-antagonist ovarian stimulation protocols in an unselected population undergoing IVF/ICSI.
    Siristatidis C; Dafopoulos K; Christoforidis N; Anifandis G; Pergialiotis V; Papantoniou N
    Gynecol Endocrinol; 2017 Dec; 33(12):968-971. PubMed ID: 28508691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant follicle-stimulating hormone (rFSH) supplemented with low-dose human chorionic gonadotropin compared with rFSH alone for ovarian stimulation for in vitro fertilization.
    Van Horne AK; Bates GW; Robinson RD; Arthur NJ; Propst AM
    Fertil Steril; 2007 Oct; 88(4):1010-3. PubMed ID: 17434503
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol.
    Salgueiro LL; Rolim JR; Moura BR; Machado SP; Haddad C
    JBRA Assist Reprod; 2016 Aug; 20(3):123-6. PubMed ID: 27584604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study.
    Blockeel C; De Vos M; Verpoest W; Stoop D; Haentjens P; Devroey P
    Hum Reprod; 2009 Nov; 24(11):2910-6. PubMed ID: 19617207
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.
    De Placido G; Alviggi C; Perino A; Strina I; Lisi F; Fasolino A; De Palo R; Ranieri A; Colacurci N; Mollo A;
    Hum Reprod; 2005 Feb; 20(2):390-6. PubMed ID: 15576390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study.
    Olgan S; Humaidan P
    Reprod Biol; 2017 Mar; 17(1):105-110. PubMed ID: 28173995
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial.
    Kyrou D; Kolibianakis EM; Fatemi HM; Tarlatzis BC; Tournaye H; Devroey P
    Fertil Steril; 2011 Nov; 96(5):1112-5. PubMed ID: 21924414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of progesterone production with serum anti-Müllerian hormone levels in assisted reproductive technology cycles with corifollitropin alfa.
    Lee TH; Tzeng SL; Lee CI; Chen HH; Huang CC; Chen SU; Lee MS
    PLoS One; 2018; 13(11):e0206111. PubMed ID: 30427868
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of anti-Müllerian hormone-tailored ovarian stimulation protocols in in vitro fertilization/intracytoplasmic sperm injection cycles in women of advanced age.
    Liao CC; Lee RK; Lin SY; Lin MH; Hwu YM
    Taiwan J Obstet Gynecol; 2016 Apr; 55(2):239-43. PubMed ID: 27125408
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Corifollitropin alfa for poor responders patients, a prospective randomized study.
    Fusi FM; Zanga L; Arnoldi M; Melis S; Cappato M; Candeloro I; Di Pasqua A
    Reprod Biol Endocrinol; 2020 Jul; 18(1):67. PubMed ID: 32646462
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A pilot study comparing corifollitropin alfa associated with hp-HMG versus high dose rFSH antagonist protocols for ovarian stimulation in poor responders.
    Mendret-Pellerin S; Leperlier F; Reignier A; Lefebvre T; Barrière P; Fréour T
    Hum Fertil (Camb); 2020 Jun; 23(2):93-100. PubMed ID: 30129813
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synchronization of ovarian stimulation with follicle wave emergence in patients undergoing in vitro fertilization with a prior suboptimal response: a randomized, controlled trial.
    Baerwald A; Anderson P; Yuzpe A; Case A; Fluker M
    Fertil Steril; 2012 Oct; 98(4):881-7.e1-2. PubMed ID: 22819187
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
    Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
    J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Volume-based follicular output rate improves prediction of the number of mature oocytes: a prospective comparative study.
    Rodríguez-Fuentes A; Rouleau JP; Vásquez D; Hernández J; Naftolin F; Palumbo A
    Fertil Steril; 2022 Nov; 118(5):885-892. PubMed ID: 36116981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
    Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
    Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients.
    Hwang JL; Chen SU; Chen HJ; Chen HF; Yang YS; Chang CH; Seow KM; Tzeng CR; Lin YH
    J Formos Med Assoc; 2018 Jun; 117(6):535-540. PubMed ID: 28830648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.